Elevance Health, Inc. with ticker code (ELV) now have 19 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $625.00 and $388.00 calculating the average target price we see $505.44. Now with the previous closing price of $368.90 and the analysts are correct then there would likely be a percentage uptick in value of 37.0%. Also worth taking note is the 50 day moving average now sits at $397.69 and the 200 moving average now moves to $493.81. The market capitalization for the company is 84.84B. The stock price is currently at: $365.83 USD
The potential market cap would be $116,248,587,680 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 13.32, revenue per share of $747.41 and a 5.84% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
